YDS Pharmatech

Are you working on challenging targets that don’t have enough data to feed conventional AI drug design engines? What if you could simultaneously optimize your compounds for desired efficacy, specificity, and synthesizability – without needing abundant historic data? With YDS Pharmatech’s drug discovery platform -MERES- you can achieve lead candidates in 8 weeks with as little as one molecule as input. MERES, short for modify-evaluate-reinforce-evolve-sampling, is our unique proprietary AI plus biophysics drug design engine that has already accelerated programs for biopharma partners, increased a PROTAC candidate binding to a challenging target by 100-fold, discovered the world’s first alphavirus inhibitor, and generated new IP for an allosteric kinase inhibitor.